| Autor: |
Helena Ferreira Bruzzi Porto, Gabriela C.K. Lopes, Hannah B.V. Bekierman, Sérgio Altino De Almeida, Felipe Da Matta Andreiuolo, Evandro Lucena, Sandip Pravin Patel, Vinicius Freire, Daniel Herchenhorn |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Case Reports in Oncology, Vol 17, Iss 1, Pp 950-959 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
1662-6575 |
| DOI: |
10.1159/000540573 |
| Popis: |
Introduction: High-grade treatment-emergent neuroendocrine prostate cancer (T-NEPC) is a rare subtype of prostate cancer with limited therapeutic options and poor prognosis. Understanding biomarkers that influence the efficacy of immune checkpoint inhibitors (IO) is vital to form a better therapeutic arsenal for these patients. Case Presentation: We describe an impressive response to IO combination immunotherapy with ipilimumab plus nivolumab (Ipi/nivo) in a patient with T-NEPC who had failed standard treatment approaches. The patient was showing signs of a rapid decline in quality of life despite his prostate-specific antigen levels remaining undetectable and had no previous response to standard therapies. The results of the next-generation sequencing DNA analysis demonstrated the presence of intermediary tumor burden, an ATM mutation and a rare SF3B1 (G742D) mutation, and served as rational for IO therapy in this patient. Conclusions: This case highlights the genetic profile of tumor with a rare combination of ATM and SF3B1 mutations that could be further explored as biomarkers for IO therapy in T-NEPC and other tumor types. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
